{
    "organizations": [],
    "uuid": "76691e2802c4b0b5e1daa6444a7bc27feed63cb6",
    "author": "",
    "url": "https://www.reuters.com/article/brief-alder-biopharmaceuticals-new-data/brief-alder-biopharmaceuticals-new-data-demonstrated-eptinezumab-increased-migraine-free-intervals-in-patients-with-episodic-migraine-idUSFWN1S20YA",
    "ord_in_thread": 0,
    "title": "BRIEF-Alder Biopharmaceuticals - New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals In Patients With Episodic Migraine",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Alder Biopharmaceuticals Inc:\n* ALDER BIOPHARMACEUTICALSÂ® NEW DATA DEMONSTRATED EPTINEZUMAB INCREASED MIGRAINE-FREE INTERVALS (UP TO 32.5 DAYS) AND IMPROVED QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH EPISODIC MIGRAINE\n* ALDER BIOPHARMACEUTICALS INC - IN TRIAL, PATIENTS EXPERIENCED A SIGNIFICANT REDUCTION IN MIGRAINE DAYS AND IMPROVED QUALITY-OF-LIFE OUTCOMES\n* ALDER BIOPHARMA- IN POST HOC ANALYSIS, PATIENTS ACHIEVING A 75 PERCENT OR GREATER RESPONSE RATE HAD OVER AN 8-FOLD INCREASE IN DAYS BETWEEN MIGRAINES\n* ALDER BIOPHARMACEUTICALS INC - 29.7 PERCENT OF PATIENTS ACHIEVED A 75 PERCENT OR GREATER REDUCTION IN MIGRAINE DAYS FROM BASELINE\n* ALDER BIOPHARMACEUTICALS INC - OBSERVED SAFETY PROFILE FOR PROMISE 1, TO DATE, IS CONSISTENT WITH PREVIOUSLY REPORTED EPTINEZUMAB STUDIES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-25T15:33:00.000+03:00",
    "crawled": "2018-04-25T15:55:44.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "alder",
        "biopharmaceuticals",
        "inc",
        "alder",
        "new",
        "data",
        "demonstrated",
        "eptinezumab",
        "increased",
        "interval",
        "day",
        "improved",
        "outcome",
        "patient",
        "episodic",
        "migraine",
        "alder",
        "biopharmaceuticals",
        "inc",
        "trial",
        "patient",
        "experienced",
        "significant",
        "reduction",
        "migraine",
        "day",
        "improved",
        "outcome",
        "alder",
        "post",
        "hoc",
        "analysis",
        "patient",
        "achieving",
        "percent",
        "greater",
        "response",
        "rate",
        "increase",
        "day",
        "migraine",
        "alder",
        "biopharmaceuticals",
        "inc",
        "percent",
        "patient",
        "achieved",
        "percent",
        "greater",
        "reduction",
        "migraine",
        "day",
        "baseline",
        "alder",
        "biopharmaceuticals",
        "inc",
        "observed",
        "safety",
        "profile",
        "promise",
        "date",
        "consistent",
        "previously",
        "reported",
        "eptinezumab",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}